Biohaven Pharmaceutical Holding Company Ltd. (BHVN) financial statements (2023 and earlier)

Company profile

Business Address 215 CHURCH STREET
NEW HAVEN, CT 06510
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments365355317264131
Cash and cash equivalents172132317264131
Short-term investments193223   
Restricted cash and investments 1   
Receivables308120   
Inventory, net of allowances, customer advances and progress billings8140   
Inventory8140   
Prepaid expense89 475
Other current assets3415000
Other undisclosed current assets 73800
Total current assets:876603328272137
Noncurrent Assets
Inventory, Noncurrent88    
Finance lease, right-of-use asset9  
Operating lease, right-of-use asset56 
Property, plant and equipment159862
Long-term investments and receivables 15118
Long-term investments 15118
Intangible assets, net (including goodwill)5639   
Intangible assets, net (excluding goodwill)5639   
Restricted cash and investments11   
Other undisclosed noncurrent assets2727200
Total noncurrent assets:20184161810
TOTAL ASSETS:1,077687344290147
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities47221466209
Accounts payable524814115
Accrued liabilities4201665295
Financial instruments subject to mandatory redemption, settlement terms, share value, amount6363   
Total current liabilities:53427766209
Noncurrent Liabilities
Long-term debt and lease obligation711   
Finance lease, liability48 
Operating lease, liability33 
Liabilities, other than long-term debt18114714121
Financial instruments subject to mandatory redemption, settlement terms, share value, amount156112104  
Other liabilities1221021
Derivative instruments and hedges, liabilities131438  
Other undisclosed noncurrent liabilities1,0385851441184
Total noncurrent liabilities:1,2267422861205
Total liabilities:1,7601,01935213915
Temporary equity, carrying amount6060   
Stockholders' equity
Stockholders' equity attributable to parent(739)(390)(7)151132
Common stock1,6771,250881554311
Additional paid in capital17099844024
Accumulated other comprehensive income (loss)(0)0   
Accumulated deficit(2,586)(1,739)(972)(444)(203)
Stockholders' equity attributable to noncontrolling interest(4)(2)   
Total stockholders' equity:(743)(392)(7)151132
TOTAL LIABILITIES AND EQUITY:1,077687344290147

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues46364   
Cost of revenue
(Cost of Goods and Services Sold)
(92)(18)   
Gross profit:37146   
Operating expenses(1,075)(691)(479)(225)(108)
Operating loss:(704)(645)(479)(225)(108)
Nonoperating expense(139)(113)(49)(16)(19)
Other nonoperating expense(7)(4)(0)(0)(19)
Interest and debt expense(1)(0)(13)(0)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes  1301
Loss from continuing operations before equity method investments, income taxes:(844)(759)(528)(240)(126)
Other undisclosed income from continuing operations before income taxes10   
Loss from continuing operations before income taxes:(843)(758)(528)(240)(126)
Income tax expense(5)(10)(0)(0)(1)
Net loss:(848)(769)(529)(241)(127)
Net income attributable to noncontrolling interest22   
Net loss attributable to parent:(847)(767)(529)(241)(127)
Other undisclosed net loss available to common stockholders, basic    (12)
Net loss available to common stockholders, diluted:(847)(767)(529)(241)(139)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(848)(769)(529)(241)(127)
Other comprehensive income (loss)(0)0   
Comprehensive loss:(849)(768)(529)(241)(127)
Comprehensive income, net of tax, attributable to noncontrolling interest22   
Comprehensive loss, net of tax, attributable to parent:(847)(766)(529)(241)(127)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: